Pharvaris (PHVS) Cash from Financing Activities (2020 - 2026)

Pharvaris (PHVS) posted Cash from Financing Activities of -$72017.2 for Q1 2026, down 122.79% on a QoQ basis from $316027.3 in Q4 2025, and up 9.25% year-over-year from -$65917.1 in Q1 2025.

Pharvaris (PHVS) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Pharvaris' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$72017.2 for Q1 2026.

  • Quarterly Cash from Financing Activities rose 9.25% year-over-year to -$72017.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $187.8 million (up 9464.31% YoY) and the FY2025 annual result came in at $181.5 million, up 6163.71% from the prior year.
  • Cash from Financing Activities was -$72017.2 for Q1 2026 at Pharvaris, down from $316027.3 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $69456.2 billion in Q2 2023 and bottomed at -$69434.8 billion in Q3 2023.
  • A 5-year average of $1.3 billion and a median of $316027.3 in 2025 frame the typical range for Cash from Financing Activities.
  • Peak annual rise in Cash from Financing Activities reached 728626264.9% in 2023, while the deepest fall reached 524286449879.51% in 2023.
  • Pharvaris' Cash from Financing Activities stood at -$163045.7 in 2022, then soared by 172816.54% to $281.6 million in 2023, then sank by 99.79% to $604998.1 in 2024, then plunged by 47.76% to $316027.3 in 2025, then tumbled by 122.79% to -$72017.2 in 2026.
  • Business Quant data shows PHVS's Cash from Financing Activities at -$72017.2 in Q1 2026, $316027.3 in Q4 2025, and $187.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 67,102.16 Bn 67,101.87 Bn - 30.14 Mn
2 Nanobiotix 1,909.44 Bn 1,909.38 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - 53,000.00
4 BeOne Medicines 471.58 Bn 466.79 Bn 1.35 Bn 68.63 Mn
5 Vertex Pharmaceuticals 121.97 Bn 114.72 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 69.93 Bn 61.18 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.68 Bn 62.68 Bn - -
8 Argenx Se 55.80 Bn 50.61 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.37 Bn 34.36 Bn 959.66 Mn 15.71 Mn
10 Pharvaris 2.22 Bn 1.93 Bn - -72,017.25

Historic Data

Download Data
DateValue
Mar 31, 2026 -72,017.25
Mar 31, 2026 -72,017.25
Dec 31, 2025 316,027.34
Dec 31, 2025 316,027.34
Sep 30, 2025 187.56 Mn
Sep 30, 2025 187.56 Mn
Jun 30, 2025 -25,921.88
Jun 30, 2025 -25,921.88
Mar 31, 2025 -79,361.53
Mar 31, 2025 -79,361.53
Dec 31, 2024 604,998.11
Dec 31, 2024 604,998.11
Sep 30, 2024 1.09 Mn
Sep 30, 2024 1.09 Mn
Jun 30, 2024 348,291.29
Jun 30, 2024 348,291.29
Mar 31, 2024 863,703.23
Mar 31, 2024 863,703.23
Dec 31, 2023 281.61 Mn
Dec 31, 2023 281.61 Mn